Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Metabolic

VK2735

InvestigationalAHuman trial evidenceWhat this means

VK2735 is an investigational peptide that activates both the GLP-1 and GIP receptors and is being studied as a once-weekly injection and as an oral formulation. One 13-week phase 2 randomized trial has been published, and phase 3 trials are under way. It is not an approved medicine, and this entry is for research information only.

US status
Investigational
Evidence
Grade A
Half-life
A numerical half-life was not located; the VENTURE report states only that a side chain extends half-life after subcutaneous injection
Class
Dual GLP-1 receptor / GIP receptor agonist (investigational)
Studied in: Appetite & body weight · Class: GIP and glucagon co-agonists
More
Log a sample
Dosing referenceCycle-length evidenceCalculate a draw
Unbranded reference vial illustrating VK2735; not an actual product
Research reference, not advice. Study facts, not instructions. Amiravo sells nothing; some links are referrals.Read the full notice

Key takeaways

  • In the 13-week VENTURE phase 2 trial, mean body-weight change ranged from -9.1% (2.5 mg) to -14.7% (15 mg) with weekly VK2735 versus -1.7% with placebo 1.
  • At least 5% body-weight reduction was reported in 93% of VK2735 recipients versus 12% with placebo 1.
  • Gastrointestinal adverse events affected 51-83% of VK2735 groups versus 37% with placebo, and the authors reported that they became less frequent after titration 1.
  • VENTURE was short, sponsor-funded and not powered for most between-group comparisons, and the receptor-binding data it cites are unpublished company data 1.
  • VK2735 is not FDA-approved; 78-week phase 3 trials in people with and without type 2 diabetes are registered as active 5,6,9.

Development stage

Where VK2735 sits between laboratory work and regulatory approval.

  1. Preclinical
  2. Phase 1
  3. Phase 2
  4. Phase 3 (current)
  5. Approved

Stage comes from the regulatory record and ClinicalTrials.gov studies naming the compound (for compounds approved nowhere, only completed trials or trials with posted results count) (checked 2026-10-24). A registered trial is not a result.

Mechanism of action

VK2735 is described as a GLP-1 receptor and GIP receptor dual agonist that incorporates the activities of both incretin hormones 1.

Receptor binding

The VENTURE report states that VK2735 binds with high affinity to the GLP-1 receptor (IC50 188 nM) and the GIP receptor (IC50 325 nM), citing unpublished data from the sponsor 1. No independent peer-reviewed pharmacology paper was located for this entry 1.

Half-life extension and oral development

The peptide contains a side chain that imparts an extended half-life when given by subcutaneous injection 1. The developer has also registered a 13-week oral dose-finding trial in which VK2735 is described as a peptide GLP-1 and GIP dual agonist given daily 4.

Research overview

Human research

The only peer-reviewed human efficacy report located is the 13-week phase 2 VENTURE trial of weekly subcutaneous VK2735 in 176 adults with obesity or overweight 1. A phase 1 study 3, an oral phase 2 study 4 and four phase 3 trials 5,6,7,8 are registered, without posted results for those reviewed.

Animal research

The VENTURE report describes preclinical findings only as unpublished sponsor data, and no peer-reviewed animal study was located for this entry 1.

In-vitro research

Binding IC50 values of 188 nM (GLP-1 receptor) and 325 nM (GIP receptor) are cited in the VENTURE report as unpublished sponsor data 1.

Key studies

  1. Bays et al., Obesity (VENTURE) (2026)
    Randomized, double-blind, placebo-controlled, dose-ranging phase 2, 13 weeks (NCT06068946)
    Model: Humans (176 adults with obesity or overweight and at least one weight-related comorbidity, no diabetes)

    Mean body-weight reduction ranged from 9.2 kg (9.1%) at 2.5 mg to 14.6 kg (14.7%) at 15 mg versus 1.8 kg (1.7%) with placebo 1.

  2. Phase 1 registry record (NCT05203237) (2021)
    Randomized, double-blind, placebo-controlled single and multiple ascending dose study, including a 28-day oral part
    Model: Healthy adults and adults with increased BMI (92 enrolled)

    Registered as completed; results were not posted on the registry record reviewed 3.

  3. VENTURE oral registry record (NCT06828055) (2024)
    Randomized, double-blind, placebo-controlled 13-week oral dose-finding phase 2
    Model: Adults with obesity or overweight (280 enrolled)

    Registered as completed with a primary outcome of percent change in body weight at 13 weeks; no results were posted on the registry record reviewed 4.

Doses used in published trials

What investigators administered in the cited studies, recorded as a fact about those studies. Not a protocol and not a recommendation.

Full dosing reference, study durations and vial arithmetic →
  • In VENTURE (NCT06068946), participants were randomized 1:1:1:1:1 to weekly subcutaneous VK2735 at 2.5, 5.0, 10 or 15 mg or matched placebo for 13 weeks, with titration to the final dose; the 15 mg group started at 5.0 mg and the others at 2.5 mg 1,2.
  • VANQUISH 1 (NCT07104500) is registered as a 78-week trial of once-weekly VK2735 7.5 mg, 12.5 mg or 17.5 mg versus placebo in an estimated 4,500 adults without type 2 diabetes 5.
  • VANQUISH 2 (NCT07104383) is registered with the same three dose arms and placebo in an estimated 1,100 adults with type 2 diabetes 6.
  • The oral phase 2 trial (NCT06828055) is registered with six daily oral dose arms and placebo over 13 weeks in 280 participants 4.
  • SUNRISE 1 (NCT07868835) is registered as a 68-week trial of three oral once-daily dose levels versus placebo in an estimated 560 adults without type 2 diabetes, and SUNRISE 2 (NCT07868939) as a trial in adults with type 2 diabetes 7,8.
  • VENTURE randomized 176 participants (about 35 per group); the total study lasted 23 weeks, comprising 4 weeks of screening, 13 weeks of treatment and about 6 weeks of safety follow-up 1.
  • The phase 1 registry record (NCT05203237; 92 enrolled) lists Part A (single escalating subcutaneous doses in healthy participants), Part B (escalating once-weekly subcutaneous doses for four weeks) and Part C (escalating once-daily oral doses for 28 days), each with placebo; dose amounts are not stated in the registry fields 3.
  • SUNRISE 2 (NCT07868939) is registered as a 68-week trial of three oral once-daily VK2735 dose levels versus placebo in an estimated 560 adults with type 2 diabetes 8.

VK2735 draw calculator

Pick the vial strength and how much water is added, then enter an amount to see the units to draw. Arithmetic only, not a recommendation.

1 · Vial strength
2 · Water added
3 · Amount per draw
4 · Syringe
Your mix
10 mg + 2 mL water = 5 mg/mL
10 units holds 0.5 mg (500 mcg)
Draw toEnter an amount in step 3
0102030405060708090100
U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Watermg/mLDraw
0.5 mL20—
1 mL10—
1.5 mL6.667—
2 mL5—
2.5 mL4—
3 mL3.333—
5 mL2—

Published adverse-event data

Reported in the cited trials or product labels. Frequencies apply to the stated population and do not transfer to other settings.

  • Gastrointestinal disorders (any)
    51-83% across VK2735 groups versus 37% placebo
    VENTURE, 13 weeks 1 · Mostly mild or moderate; grade 3 in up to 9% of a dose group
  • Nausea
    26-63% across VK2735 groups versus 20% placebo
    VENTURE 1 · Most common GI event; highest in week 1 of the 15 mg group
  • Vomiting
    9-29% across VK2735 groups versus 0% placebo
    VENTURE 1 · Mild or moderate
  • Constipation
    20-29% across VK2735 groups versus 11% placebo
    VENTURE 1 · Mild or moderate
  • Adverse event leading to treatment discontinuation
    3-20% across VK2735 groups (20% at 15 mg) versus 0% placebo
    VENTURE 1 · Led to treatment discontinuation
  • Treatment-emergent serious adverse events
    3-6% across VK2735 groups versus 3% placebo
    VENTURE 1 · Serious; 10 of 12 events judged unrelated by investigators
  • Anti-drug antibodies
    9-23% across VK2735 groups
    VENTURE 1 · Clinical significance not established in the report

Emerging safety signals

  • One participant had atrial fibrillation (judged possibly related) and dehydration (judged probably related), which led to study discontinuation; the results text places this participant in the 5.0 mg group, while the corresponding adverse-event table footnote sits in the 15 mg column, so the dose group is uncertain 1. 1 (2026)
  • Mean heart rate rose from baseline by 3.3 to 9.3 beats per minute across VK2735 groups versus 1.4 with placebo in the trial's cardiometabolic table; the trial was 13 weeks long with about 35 participants per group 1. 1 (2026)
  • One death (head trauma from a fall) occurred in the 15 mg group and was assessed as not related to the study drug 1. 1 (2026)

What is not known: No regulatory approval exists, so there is no label. The elimination half-life and peer-reviewed preclinical pharmacology were not located. The only published efficacy trial lasted 13 weeks and was not powered for most comparisons between groups. Results of the oral phase 2 trial were not posted on the registry record or published in the sources reviewed. Long-term efficacy, safety and outcome data await the 78-week phase 3 trials. The published trial was funded by the developer, and several authors are company employees.

Background viewing

We haven't found a clinician video focused on VK2735 yet. Meanwhile, this widely watched talk covers the science of aging in general. It does not discuss VK2735.

David Sinclair, PhD (Harvard Medical School) on the biology of aging
The Diary Of A CEO · 6.9M views · 2026

These creators are not affiliated with Amiravo and do not endorse Amiravo or any product linked on this site. Nothing here is medical advice. Video views counted on YouTube as of Oct 24, 2026.

Regulatory status

Status
Investigational as of 22 October 2026. An openFDA query of Drugs@FDA on that date returned no application record for VK2735 9, and its phase 3 trials are registered as active or not yet recruiting 5,6,7,8.
United States (FDA)
VK2735 is investigational; an openFDA query of Drugs@FDA application data on 22 October 2026 returned no application record for it 9.
Sport (WADA)
VK2735 is not named in the 2026 Prohibited List text reviewed. Section S0 covers pharmacological substances not addressed elsewhere on the List that have no current approval by any governmental regulatory health authority for human therapeutic use, including drugs under clinical development; athletes should consult WADA directly 10.

Status varies by country and changes over time. How we describe regulatory status.

Quality and testing notes

No PubChem compound record for VK2735 was returned on 22 October 2026, and its structure has not been published in the sources reviewed, so a reference molecular weight could not be verified [11]. A certificate of analysis for a VK2735 research material would be expected to show HPLC purity, mass-spectrometry identity, endotoxin and net peptide content; without a public structure, identity claims cannot be checked against an independent reference [1, 11].

How purity testing works · Reading a certificate of analysis

Check a VK2735 certificate of analysis

Storage and handling

Storage conditions for research material are set by the supplier's documentation; lyophilized peptides are generally sensitive to heat, light and moisture.

Frequently asked questions

What is VK2735?
VK2735 is an investigational peptide dual agonist of the GLP-1 and GIP receptors with a side chain that extends its half-life after injection 1.
Is VK2735 approved by the FDA?
No. An openFDA query of Drugs@FDA on 22 October 2026 returned no application record 9.
What did the phase 2 trial show?
Over 13 weeks, mean body-weight change ranged from -9.1% to -14.7% across four doses versus -1.7% with placebo 1.
Is there an oral version?
Yes. A 13-week oral phase 2 trial is registered as completed, and two oral phase 3 trials are registered as not yet recruiting 4,7,8. Peer-reviewed oral results were not located for this entry 4.
How does it compare with tirzepatide?
Both act at GLP-1 and GIP receptors 1. No head-to-head trial was located, and a 13-week trial cannot be compared directly with 72-week phase 3 trials 1.
What adverse events were reported?
Mainly gastrointestinal events such as nausea, constipation and vomiting, which the authors reported became less frequent after titration 1.

Latest indexed research

Search all studies on VK2735 (PubMed, Europe PMC, ClinicalTrials.gov)

Listed by publication type from the index record. Inclusion is not an endorsement; open the source to read the findings.

Revision history

Meaningful changes to this entry, with dates and sources. Last reviewed Oct 23, 2026. Typo and layout fixes are not listed.

References

  1. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study Obesity (Silver Spring). 2026
  2. VK2735 for Weight Management Phase 2 (VENTURE, NCT06068946), registry record ClinicalTrials.gov. 2023
  3. Phase 1 Study to Evaluate the Safety and Tolerability of VK2735 (NCT05203237), registry record ClinicalTrials.gov. 2021
  4. VK2735 for Weight Management Phase 2 (VENTURE Oral Dosing, NCT06828055), registry record ClinicalTrials.gov. 2024
  5. VK2735 for Weight Management Phase 3 (VANQUISH 1, NCT07104500), registry record ClinicalTrials.gov. 2025
  6. VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2, NCT07104383), registry record ClinicalTrials.gov. 2025
  7. Oral VK2735 for Weight Management Phase 3 (SUNRISE 1, NCT07868835), registry record ClinicalTrials.gov. 2026
  8. Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2, NCT07868939), registry record ClinicalTrials.gov. 2026
  9. Drugs@FDA application data queried through openFDA for VK2735 (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
  10. World Anti-Doping Agency International Standard Prohibited List 2026 WADA. 2026
  11. PubChem compound name search for VK2735 (no compound record returned on 22 October 2026) PubChem. 2026

Last reviewed October 23, 2026 by the Amiravo editorial team.

Read our editorial policy · Report an error on this page

Need the math?

Laboratory arithmetic with every formula shown.

For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement. This page is educational and is not medical advice.

Unbranded reference vial illustrating VK2735; not an actual product

Unbranded reference image. Amiravo does not produce, supply or sell this compound.

Specifications

Format
Lyophilized vial
Type
Single compound

Chemical identifiers are shown only when verified against PubChem.

Research stats

How much has been published, not how good it is.

PubMed records
2
Indexed as human research
1
Animal-only research
0
Randomized controlled trials
1
Registered trials
8
Trials with posted results
0
2006: 02007: 02008: 02009: 02010: 02011: 02012: 02013: 02014: 02015: 02016: 02017: 02018: 02019: 02020: 02021: 02022: 02023: 02024: 02025: 02026: 220062026
PubMed records per year (current year is partial).

Counts from title/abstract searches of PubMed, ClinicalTrials.gov, openFDA and NIH RePORTER, checked 2026-10-24. Names shared with other substances can inflate counts. FAERS reports are spontaneous and do not establish cause. Funding shows interest, not evidence. Method

Follow VK2735

See every new citation, evidence-grade or status change and correction in My Research, with optional email alerts. Free account.